T he risk of secondary cardiovascular events (CVE) varies across the spectrum of patients with ischemic stroke. Despite guideline-based optimal treatment of patients with transient ischemic attack and stroke including urgent management in specialized units, broad diagnostic workup, rapid treatment with antithrombotic agents, and other stroke-prevention strategies, recent studies suggest a considerable residual risk of 6.2% for CVE and 5.1% for stroke within 1-year follow-up. 1 In view of these data, there is still great need to identify additional factors impacting the patients' risk beyond traditional risk factors Objective-Gut microbiota-dependent metabolites, in particular trimethylamine N-oxide (TMAO), have recently been reported to promote atherosclerosis and thrombosis. Here, we examined for the first time the relation of TMAO and the risk of incident cardiovascular events in patients with recent first-ever ischemic stroke in 2 independent prospective cohorts. Moreover, the link between TMAO and proinflammatory monocytes as a potential contributing factor for cardiovascular risk in stroke patients was studied. Approach and Results-In a first study (n=78), higher TMAO plasma levels were linked with an increased risk of incident cardiovascular events including myocardial infarction, recurrent stroke, and cardiovascular death (fourth quartile versus first quartile; hazard ratio, 2.31; 95% CI, 1.25-4.23; P<0.01). In the second independent validation cohort (n=593), high TMAO levels again heralded marked increased risk of adverse cardiovascular events (fourth quartile versus first quartile; hazard ratio, 5.0; 95% CI, 1.7-14.8; P<0.01), and also after adjustments for cardiovascular risk factors including hypertension, diabetes mellitus, LDL (low-density lipoprotein) cholesterol, and estimated glomerular filtration rate (hazard ratio, 3.3; 95% CI, 1.2-10.9; P=0.04). A significant correlation was also found between TMAO levels and percentage of proinflammatory intermediate CD14 ++ CD16 + monocytes (r=0.70; P<0.01). Moreover, in mice fed a diet enriched with choline to increase TMAO synthesis, levels of proinflammatory murine Ly6C high monocytes were higher than in the chowfed control group (choline: 9.2±0.5×10 3 per mL versus control: 6.5±0.5×10 3 per mL; P<0.01). This increase was abolished in mice with depleted gut microbiota (choline+antibiotics: 5.4±0.7×10 3 per mL; P<0.001 versus choline). Conclusions-The present study demonstrates for the first time a graded relation between TMAO levels and the risk of subsequent cardiovascular events in patients with recent prior ischemic stroke. Our data support the notion that TMAO-related increase of proinflammatory monocytes may add to elevated cardiovascular risk of patients with increased TMAO levels. Visual Overview-An online visual overview is available for this article.
that may help to more accurately estimate patient vulnerability for subsequent CVE improving preventive concepts.
Recently, an important contribution of gut microbiota in pathobiological processes including metabolic, 2 immunologic, 3 and cardiovascular diseases 4 has been suggested. Notably, metabolomics combined with mechanistic animal model studies have led to a proposed potential link between dietary nutrients, such as choline and carnitine, and their gut microbiota-dependent metabolism to trimethylamine N-oxide (TMAO), and atherosclerosis. 4, 5 There is considerable evidence linking the metaorganismal TMAO pathway to the development of atherosclerosis and thrombosis in animal models and incident cardiovascular disease risks. In particular, proatherogenic effects of microbe-dependent TMAO formation include enhanced macrophage cholesterol accumulation and subsequent foam cell formation, 4 proinflammatory changes in the artery wall, 6 and promotion of both platelet hyperreactivity and enhanced arterial thrombosis potential. 7 With regard to recent observations on the relation between TMAO and the risk for CVE in patients with acute coronary syndrome, 8 we sought to evaluate the prognostic value of TMAO levels in patients with recent first-ever ischemic stroke and investigate a potential interaction between TMAO and proinflammatory circuits that promote thrombotic complications of patients at high risk.
In recent years, a critical role of monocyte subsets with distinct expressions of the lipopolysaccharide receptor CD14 and the FcγIII (Fc gamma receptor III) receptor CD16 has been unveiled for formation, propagation, and vulnerability of atherosclerotic lesions. 9, 10 In particular, the intermediate CD14 ++
CD16
+ monocytes have been identified to independently predict future CVE in large patient cohorts of coronary artery disease, chronic kidney disease, and peripheral artery disease. [11] [12] [13] The intermediate CD14 ++ CD16 + monocytes are considered as a subset with particular proinflammatory functions 14 known to secrete high amounts of inflammatory cytokines, such as TNF (tumor necrosis factor)-α, on activation. 15 In patients with ischemic stroke, the increased number of the intermediate monocyte subset has been strongly correlated with the progression and severity of brain infarction. 16 On the basis of advanced cluster analysis, the intermediate subset has been closely related to proinflammatory murine Ly6C high monocytes 10, 15, 17 allowing to investigate the biology of these monocytes in experimental settings.
Here, we evaluated for the first time the relationship between circulating TMAO levels and incident CVE in 2 independent prospective cohorts of patients with ischemic stroke. Moreover, we examined the relation between TMAO and the level of proinflammatory monocyte subsets as a potential contributing factor to trigger CVE both in patients and in a mouse model of antibiotics-induced depletion of the gut microbiota. The results may provide novel insights into the relationship between the gut microbiota-related metabolite TMAO, proinflammatory monocytes, and clinical prognosis in patients with stroke.
Materials and Methods
The data that support the findings of this study are available from the corresponding author upon reasonable request. Details of the major resources and detailed methods can be found in the online-only Data Supplement.
Study Populations and Study Design
Two prospective cohorts of patients with first-ever ischemic stroke were examined. The primary outcome measure of both cohorts was a combined vascular end point composed of myocardial infarction (MI), recurrent stroke, and cardiovascular death during 1-year followup on a structured interview with the patient or their relatives and, if indicated, with additional information from the hospital or physician.
The inclusion criteria of both studies were (1) age 18 years, (2) first-ever acute stroke that occurred with stroke onset in the last 7 days, and (3) written informed consent by patient or legal guardian before study participation. The exclusion criteria were (1) prior stroke, (2) patients presenting brain tumor or brain metastasis, and (3) participation in an intervention study. Both studies were approved by the respective local research ethics committee. All participants with adjudicated diagnosis of ischemic stroke provided written informed consent and were prospectively enrolled. For evaluation of acute ischemic stroke, diffusion-weighted magnetic resonance imaging (Siemens Verio 3.0 T) was performed.
In the first cohort, 78 patients with complete data on primary outcome were enrolled. The relation of the gut microbe-dependent metabolite TMAO with the risk of subsequent (1 year) cardio-and cerebrovascular events (CVE) including MI, recurrent stroke, and cardiovascular death was examined.
After finding a significant relation between TMAO with the cardiovascular risk in the first cohort, a second larger independent validation cohort including 608 patients from the PROSCIS study (Prospective Cohort With Incident Stroke) with first-ever stroke conducted at the Center for Stroke Research Berlin in Germany (PROSCIS-B: Center for Stroke Research Berlin, Charité University Hospital) was examined with 1-year follow-up to evaluate whether the observed relation persists in an independent nonoverlapping patient population. Study protocol and design of the PROSCIS study were described previously.
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Blood Tests
Laboratory workup was performed for total cholesterol, LDL (lowdensity lipoprotein) and high-density lipoproteins, triglyceride, C-reactive protein, and full blood count. Blood samples were immediately processed and frozen at −80°C for further analyses. Levels of choline and TMAO were quantified by stable isotope dilution liquid chromatography with online tandem mass spectrometry as previously described, 19 Figure I in the online-only Data Supplement.
Mouse Experiments
All animals were bred, raised, and housed in the facilities of the Forschungseinrichtungen für Experimentelle Medizin (Charité-University Medicine Berlin, Germany) under specific pathogen-free conditions. Adult (10 weeks of age) C57BL/6J mice (Charles River) were placed on normal chow (0.2% choline) or choline-supplemented diets (1.3% choline; Ssniff, Soest, Germany) for 3 weeks before monocyte subset analysis. At the end of the 3-week period, mice were euthanized for collection of blood and bone marrow (BM). Mouse experiments were approved by the research advisory committee and permitted by Landesamt für Gesundheit und Soziales Berlin.
Generation of Secondary Abiotic (Gnotobiotic) Mice
Secondary abiotic mice were generated through quintuple antibiotic treatment (+antibiotics [ABS]) for 6 weeks via the drinking water. The intestinal colonization status of the mice was controlled once a week by highly sensitive cultural analysis of fecal samples as described earlier.
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Analysis of Blood Monocyte Subsets in Mice
Blood samples were collected by cardiac puncture using EDTA-coated syringes. Whole blood (100 μL) or BM cell suspension was incubated with antibodies for 20 minutes at room temperature in the dark (major resources table in the online-only Data Supplement). After doublet exclusion, monocytes were identified as CD45 positive and CD115 positive and further selected by highly positive expression of CD11b, a marker of dendritic cells, monocytes, and granulocytes, shown in the CD11b/Ly6C plot. Monocytes were further classified according to Ly6C expression. Detailed gating strategy for identification of monocyte subsets is shown in Figure II in the online-only Data Supplement. 
Analysis of BM Hematopoietic Stem Cells and Progenitor Cells in Mice
Statistical Analyses
Database management and statistical analyses were performed with PRISM version 5.0a (GraphPad Software Inc) and SPSS version 23 (IBM SPSS).
Mouse Studies
Continuous data were subjected to the Kolmogorov-Smirnov test to determine their distribution and were expressed as mean±SD or median and range. Comparison of means was performed by independent t test, and Wilcoxon rank-sum test of medians was used if data were not normally distributed. For continuous variables, univariate correlation analyses were performed.
Human Studies
For comparison of basic patients' characteristics, continuous data were subjected to the Kolmogorov-Smirnov test to determine their distribution and were expressed as mean±SD or median and range.
Comparison of means was performed by independent t test, and Wilcoxon rank-sum test of medians was used if data were not normally distributed. Kaplan-Meier survivor curves were examined to assess the relationship between quartiles of TMAO or choline levels timing of events during follow-up and the log-rank test for statistical assessment. Cox regression forward selection was used to further characterize the relation of TMAO and choline to outcome. To determine whether TMAO was independently related to outcome, 3 Cox regression models were used: In model 1, the outcome was adjusted for sex and age; in model 2, outcome was adjusted for model 1 and cardiovascular risk factors including hypertension, diabetes mellitus, LDL cholesterol, and estimated glomerular filtration rate; and in model 3, the outcome was adjusted for model 1 and additionally for stroke severity, stroke cause (TOAST [Trial of Org 10172 in Acute Stroke Treatment]), 22 cardiovascular risk factors including hypertension, diabetes mellitus, LDL cholesterol, history of peripheral or coronary artery disease or MI. For additional comparison of the prognostic value of TMAO with regard to CVE or stroke at 1 year, receiver operating characteristic (ROC) curves were generated, and the areas under the curves (AUC) were calculated. To assess the prognostic value of TMAO in patient subgroups, χ 2 and odds ratio analyses were performed. In addition, combined ROC curve analyses of the cardiovascular risk factors diabetes mellitus, hypertension, and dyslipidemia with and without TMAO were performed to assess the additive prognostic value of TMAO over classical cardiovascular risk factors.
Parametric correlation analyses were used to evaluate the correlation between TMAO and intermediate CD14 ++
CD16
+ monocytes. Multiple linear regression analysis was performed to further assess the correlation between TMAO levels and intermediate monocyte subsets after adjustment for age, sex, and the cardiovascular risk factors including diabetes mellitus, hypertension, dyslipidemia, and smoking. Significance was assumed at a 2-sided value of P ≤0.05.
Results
Patient Characteristics
Demographic and clinical parameters, as well as laboratory test results, of all patients in the first study are shown in Table 1 and the validation study in Table 2 . We also compared these parameters between patients with the lowest plasma levels of TMAO (first quartile in the first study, n=20; in the validation study, n=148) and those with the highest plasma levels of TMAO (fourth quartile in the first study, n=20; in the validation study, n=148). In the first study, the cohort was composed of 78 sequential consenting patients with adjudicated diagnosis of ischemic stroke. In this cohort, subjects with higher TMAO levels tended to have higher creatinine levels when compared with subjects with low TMAO levels, although otherwise no differences in baseline clinical or laboratory parameters were observed between patients in the highest quartile versus the lowest quartile of TMAO levels ( Table 1 ). The second larger validation population included 593 patients in the PROSCIS who had suffered with first-ever stroke. In this cohort, subjects in the highest TMAO quartile tended to be older, had higher creatinine levels, and had lower hemoglobin levels as well as higher leukocyte counts (Table 2) when compared with subjects in the lowest TMAO quartile. Outcomes at 1 year included MI in 6 patients, stroke in 21 patients, cardiovascular death in 19 patients, and the composite CVE in 46 patients.
Plasma TMAO Levels in Relation to Subsequent CVE and in the First Study
In the first study cohort (n=78), Kaplan-Meier analyses of TMAO levels, but not its precursor, the trimethylamine-containing nutrient choline, showed a dose-dependent relationship with the risk of incident CVE including MI, recurrent stroke, and cardiovascular death (TMAO, P<0.01, Figure 1A ; choline, P=0.37, Figure 1B) . The association between TMAO and CVE was further adjusted for age, sex, hypertension, diabetes mellitus, LDL cholesterol, and smoking resulting in a significant enhanced risk with a hazard ratio (HR), 3.5 (95% CI, 1.66-7.21; P=0.001). Analysis of the linear trend across quartiles also showed a significant enhanced risk with a χ 2 of 7.0 (P<0.01).
TMAO Levels and the Risk of Subsequent CVE or Recurrent Stroke in the Validation Study
In the validation study cohort (n=593), Kaplan-Meier plots indicated a graded increased risk of combined CVE including MI, recurrent stroke, and cardiovascular death (Figure 2A ; P=0.01) and also recurrent stroke alone ( Figure 2B ; P=0.01) with increasing plasma TMAO levels, but not with plasma choline levels (Figure 2C and 2D; P=0.24 and P=0.29, respectively). The linear trend across quartiles results in a significant enhanced risk of combined CVE with a χ2 of 9.8 (P<0.01). Subjects who experienced incident CVE had higher plasma TMAO levels at presentation than those without an event at 1-year follow-up (no event: 4.91±0.18 µmol/L versus event: 7.28±0.91 µmol/L; P<0.01; Figure 3A) . Similarly, subjects who particularly experienced recurrent stroke displayed also higher plasma TMAO levels than those without recurrent stroke at 1-year follow-up (no recurrent stroke: 4.92±0.18 µmol/L versus recurrent stroke: 6.86±1.11 µmol/L; P=0.04; Figure 3A ). The dose-dependent relationship between TMAO levels and incident CVE was particularly noticeable in patients in the fourth quartile (6.07-122 µmol/L) of plasma TMAO levels compared with those in the first quartile (<2.7 µmol/L; HR unadjusted, 5.0; 95% CI, 1.7-14.8; P<0.01; Figure 3B ). Moreover, patients in the highest quartile of TMAO levels had an increased risk of CVE over the ensuing 1-year follow-up period after the adjustments for both age and sex (HR model 1, 3.4; 95% CI, 1.2-10.2; P<0.01), and even after further adjustments for cardiovascular risk factors including hypertension, diabetes mellitus, LDL cholesterol, and estimated glomerular filtration rate (HR model 2, 3.3; 95% CI, 1.2-10.9; P=0.04). In a third model, we adjusted for age and sex and additionally for stroke severity, stroke cause (TOAST), hypertension, diabetes mellitus, LDL cholesterol, Lp(a) (lipoprotein(a)), and history of peripheral or coronary artery disease or MI (HR model 2: HR, 3.4; 95% CI, 1.1-10.1; P=0.02). Moreover, patients in the fourth versus first quartile of plasma TMAO levels were at higher risk of recurrent stroke over 1-year follow-up interval (HR, 2.7; 95% CI, 1.1-6.1; P<0.01). TMAO (A, B) , but not for plasma choline (C, D), had a significantly increased risk for experiencing a recurrent cardiovascular events and recurrent stroke (A and B, respectively) . Moreover, the prognostic value of TMAO was assessed in several patient subgroups (Figure 4) . A TMAO level >.86 µmol/L was associated with an increased cardiovascular risk in patients >66 years of age, in both males and females, and in patients with hypertension. Moreover, TMAO showed clinical prognostic utility independent of traditional cardiovascular risk factors including within both diabetic and nondiabetic patients, in smokers and nonsmokers, in patients with and without dyslipidemia, in patients with normal or impaired renal function, and in patients without history of coronary artery disease (Figure 4 ).
ROC Curve Analyses of TMAO and Prognostic Utility in Patient Subgroups
Plasma TMAO Levels in Relation to Monocyte Subsets
Assessment of the proportion of intermediate CD14 ++ CD16 + monocytes revealed significant correlation with plasma levels of TMAO (r=0.70; P<0.01; Figure 5A and 5B). Additional multiple linear regression analysis was performed to assess the correlation between TMAO levels and intermediate monocyte subsets after adjustment with age, sex, and the cardiovascular risk factors diabetes mellitus, hypertension, dyslipidemia, and smoking. After adjustment, the results still demonstrated significant correlation between intermediate monocyte levels with plasma TMAO concentrations (r=0.38; P<0.01). Further analyses determined the distribution of monocyte subsets in these patients according to TMAO levels as assessed by quartiles ( Figure 5C + monocytes showed a dose-dependent increase according to TMAO levels with the highest levels being observed in patients with the highest TMAO concentrations (fourth quartile: 9.0% versus first quartile: 3.6%; P<0.01). 
Impact of the Trimethylamine-Containing Nutrient Choline on Blood and BM Monocyte Subset Distribution in Mice
The levels of Ly6C high monocytes were increased in mice on choline (1.3%) supplemented diet when compared with normal chow (control) (choline: n=6, 9.2±0.5×10 3 per mL versus control: n=6, 6.5±0.5×10 3 per mL; P=0.001). This increase was abolished in mice with depleted gut microbiota (choline+ABS: n=6, 5.4±0.7×10 3 per mL; P<0.001 versus choline; Figure 6A) Figure 6A ). To evaluate whether the shift in monocyte subsets occurs at the level of BM exit, the levels of Ly6C high and Ly6C low monocytes in the BM were analyzed. Similar to the results in the circulation, the levels of Ly6C high monocytes were increased in the BM in mice on choline-supplemented diet when compared with normal chow when compared with normal chow. Accordingly, depletion of the gut microbiota had no significant effects on HSC or on monocyte and dendritic cell progenitors levels in the BM ( Figure IV in the online-only Data Supplement).
Discussion
Our study examines for the first time the relationship between the gut microbe-derived metabolite TMAO and recurrent stroke and CVE risk among patients with ischemic stroke in 2 independent cohorts and the relationship between baseline TMAO with the level of intermediate CD14 ++
CD16
+ monocytes in patients with stroke. The results indicate the following: (1) elevated TMAO levels are dose dependently associated with an increased risk of recurrent stroke and subsequent CVE in patients after first-ever stroke; (2) this relationship holds true even after adjusting for traditional cardiovascular and cerebrovascular risk factors and initial stroke severity; and (3) blood concentrations of TMAO are closely related to the levels of proinflammatory intermediate CD14 ++
+ monocytes. Importantly, the results of the second independent validation cohort demonstrate that the observed clinical association remains robust, indicating the prognostic clinical utility of TMAO for predicting incident adverse event or thrombosis risk replicates in a totally distinct yet clinically relevant cohort.
ROC curve analyses further revealed that TMAO provides added prognostic value to traditional risk factors as a marker of 1-year cardiovascular mortality risk in these patients. At the best cutoff value with the highest sensitivity and specificity, TMAO provided prognostic information in clinically relevant patient subgroups defined according to age, sex, underlying cardiovascular risk factors, and renal dysfunction.
Notably, we found reduced renal function in patients with the highest TMAO levels. This observation may be partly because of impaired renal elimination of TMAO in these patients. However, it was also previously shown that TMAO likely contributes to the progression of renal disease by increasing tubulointerstitial fibrosis and collagen deposition. 23 Moreover, it was shown that elevated TMAO levels increased the risk of mortality in patients with chronic kidney disease. 23 Subgroup analyses in the present study showed that clinical prognostic utility of elevated TMAO was observed in both subgroups possessing normal versus impaired renal function.
Recently, intestinal microbes and their metabolic products have been identified as potential promoters for the development of cardiometabolic diseases and atherosclerosis. 24 Microbial composition studies combining clinical phenotypic data with microbial sequencing analysis have identified that an altered gut metagenome is associated, for example, with the development of metabolic disorders such as type 2 diabetes mellitus, obesity, and symptomatic atherosclerotic heart disease. 24 Early metabolomics studies, coupled with mechanistic investigations, have unveiled a specific pathway by which gut microbes contribute to atherosclerosis and cardiovascular disease. This pathway is based on particular dietary nutrients containing a trimethylamine group such as phosphatidylcholine, choline, and carnitine. In the intestine, the trimethylamine containing nutrient is subsequently degraded by a trimethylamine lyase from specific bacterial strains, and, after absorption into the portal circulation, it is further metabolized into TMAO by hepatic FMOs (flavin monooxygenases), in particular FMO3. 4, 5, [25] [26] [27] A potential mechanistic link of TMAO to the promotion of atherosclerosis was first demonstrated in animal models, in which TMAO led to increased cholesterol accumulation in macrophages and the formation of foam cells in atherosclerotic lesions by increasing the expression of the scavenger receptors (CD36 and SR-A1 [scavenger receptors class A1]) on macrophages. 4 Interestingly, a recent clinical study examining coronary artery anatomy with the SYNTAX score (Synergy Between PCI With Taxus and Cardiac Surgery) showed a dose-dependent relationship between TMAO levels and enhanced atherosclerotic burden in subjects. 28 Moreover, recent studies suppressing TMAO generation with a small molecule inhibitor of microbial trimethylamine production led to inhibition of atherosclerosis, 27 and suppression of FMO3 has been demonstrated to both lead to TMAO reduction and inhibition in atherosclerosis in animal models. 29 Notably, TMAO has been shown to promote vascular inflammation by activating mitogen-activated protein kinase, extracellular signal-related kinase, and nuclear factor-κB signaling cascade in endothelial cells. 6 Furthermore, direct injection of TMAO in rodent models promotes aortic endothelial cell activation and upregulation of adhesion proteins. 6 Recent studies with cultured endothelial cells indicate that TMAO activates the NLRP3 (NLR family pyrin domain containing 3) inflammasome, a multienzyme proinflammatory complex thought to be involved in the development of atherosclerosis. 30 While in experimental studies, a role of TMAO for inflammatory processes has been shown, our study links increased TMAO values to proinflammatory CD14 ++ CD16
+ monocytes in humans. The intermediate CD14 ++
+ monocytes are considered to promote inflammatory responses, 14 for example, by secreting high amounts of inflammatory cytokines, such as TNF-α. 15 Moreover, high expression of adhesion molecules, such as CD162/PSGL-1 (P-selectin glycoprotein ligand-1), as well as myeloperoxidase, a major source of reactive oxidant species in innate immune responses, 13 has been identified in intermediate monocytes contributing to their prothrombotic and proatherogenic properties.
Our mouse experiments further support this proposed link and suggest a shift of monocyte subset distribution toward proinflammatory Ly6C high monocytes in the BM without affecting HSC or monocyte progenitor cells.
Recent lineage-tracing and adoptive transfer studies have supported the concept that Ly6C high monocytes are the precursors to Ly6C low monocytes. 31 Thus, alteration of subset levels reflects a difference in subset conversion. Among molecular pathways to control differentiation of Ly6C low monocytes, orphan nuclear receptor-mediated signaling, such as the Nr4a1 (nuclear receptor subfamily 4) signaling, has been identified. 32 Further studies are required to dissect the underlying molecular mechanisms by which TMAO regulates monocyte subset conversion and promotes the shift toward increased Ly6C high monocytes. Despite the observed link between TMAO and its precursor choline and proinflammatory monocytes, future studies will need to clarify whether chronic exposure to trimethylamine-containing nutrients and sustained elevation in TMAO are indeed a causal trigger of (low grade) inflammatory processes leading to enhanced cardiovascular risk, and whether targeting gut microbiota-dependent TMAO generation in humans can similarly to animal models reduce incident event risks in patients.
The relationship between altered gut microbiota composition/function and different levels of the microbiota-dependent metabolite TMAO has been recently demonstrated. For example, plasma TMAO concentrations were found to be significantly associated with Prevotella and Peptococcaceae. 5 In addition, a significant positive correlation between plasma TMAO concentrations with Clostridiales and negative correlation with Faecalibacterium prausnitzii was identified. 33 Interestingly, microbial transplantation studies have also shown that TMAO production potential and both atherosclerosis 26 and thrombosis 7 and thrombosis susceptibility are transmissible traits, further supporting a role for gut microbiota-generated TMAO in atherogenesis and thrombosis risk. These findings align with our observation that the increase in Ly6C high monocytes could be prevented on depletion of the gut microbiota suggesting an instrumental role for the gut microbiota for processing inflammation-promoting metabolites.
It is tempting to speculate that metagenomics analyses of feces could reveal alterations in the abundance of specific microbes, or more importantly, microbial enzyme pathways, known to be involved in trimethylamine and TMAO formation. Measurement of the downstream functional output of such microbial alterations (ie, TMAO levels) serves as an integrated sensor of the global changes in microbial community structure and function, with respect to the metaorganismal TMAO pathway. In future investigations, it will be of interest to explore whether demonstration of an altered fecal microbiota serves as an additive predictor beyond TMAO levels of enhanced cardiovascular risk in patients at risk for ischemic stroke. A better understanding of the role of microbiota-related metabolism in patients with cerebrovascular disease may contribute to the development of novel strategies targeting the gut microbiota (eg, its enzyme systems) for both primary and secondary prevention in these patients.
Our analysis of incident CVE data in patients with stroke suggests that elevated TMAO levels are linked with an increased risk of future cardiovascular and cerebrovascular thrombotic events. This association is consistent with the recently observed role of TMAO in enhancing platelet hyperresponsiveness and thrombosis potential in vivo. 7 In addition to platelet hyperresponsiveness, the link between microbiotadependent trimethylamine/TMAO formation and increased levels of proinflammatory monocytes may add to potential pathophysiological mechanisms ultimately cumulating in increased incidence of CVE or cerebrovascular events.
In conclusion, our study suggests a novel link between TMAO and proinflammatory monocytes, as well as with an adverse cardiovascular prognosis in patients after stroke. Our findings contribute to the understanding of a potential role of gut microbiota-related mechanisms in patients with cerebrovascular disease progression and encourage further investigation of therapeutic strategies aimed at fostering a reduction in systemic levels of the gut microbial metabolite TMAO.
